

F. Synagis ® Palivizumab

Synagis® (palivizumab) injection is a covered benefit of Nevada Medicaid for recipients under the age of 2 years who meet the criteria. A Prior Authorization is required for recipients within the indications and limitations of coverage. For consideration outside these guidelines, a PA may also be submitted with supporting medical justification documentation.

1. Coverage and Limitations:

Recipients must meet one of the following criteria:

- a. Infants or children younger than 2 years of age who have:
 - i. Diagnosis of chronic lung disease of prematurity, AND
 - ii. Have required medical therapy (e.g. bronchodilator, diuretics, oxygen, corticosteroids) within 6 months to the start of the RSV season.
- b. Infants born at 28 weeks of gestation or earlier during the first RSV season, whenever that occurs during the first 12 months of life.
- c. Infants born at 29 to 32 weeks of gestation (31 weeks, 6 days or less) who are up to 6 months of age at the onset of the RSV season.
- d. Infants born at 32 to less than 35 weeks of gestation (defined as 32 weeks, 0 days through 34 weeks, 6 days) born less than 3 months before the start of the RSV season or born at any time throughout the RSV season with one of the following risk factors:
 - i. Infant attends child care or
 - ii. One or more children younger than 5 years live permanently in the child's household.
- e. Infants with congenital abnormalities of the airway or neuromuscular disease during the first year of life.
- f. Children who are 2 years of age or younger with hemodynamically significant cyanotic and acyanotic heart disease.

For initiation and termination of prophylaxis, recipients are allowed no more than a maximum of 5 doses per RSV season.

Infants born between 32 and 35 weeks of gestation are allowed no more than a maximum of 3 doses. Prophylaxis is covered until 90 days of age.

The product must be administered within the RSV season duration as indicated by the Center for Disease Control. It may be only administered between October 1st and April 30th. Only one dose (based on recipient weight) may be given in a 30 day period.

Prior Authorization approval will be given on a per RSV season basis.

Note: Providers may bill for one vial even if only part of the single-use vial was given to the recipient and the remainder of the drug was discarded. Safe handling guidelines per manufacturer must be observed (e.g. shelf life, cold chain requirements). The smallest size vial to cover the dose must be used. For example, if the appropriate dose is 120mg, one 100mg vial and one 50mg vial should be used, the provider may not bill for two 100mg vials in this case.